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ABSTRACT
Dent's disease is a rare X-linked recessive tubulopathy 
characterized by low molecular weight (LMW) proteinuria, 
hypercalciuria, nephrolcalcinosis or nephrolithiasis, proximal 
tubular dysfunction and renal failure in adulthood. Females 
are carriers and usually mildly affected. Progression to end-
stage renal failure are at the 3rd-5th decades of life in 30-80% 
of affected males. In the absence of therapy targeting for the 
molecular defect, the current care of patients with Dent’s disease 
is supportive, focusing on the prevention of nephrolithiasis 
and nephrocalcinosis. We present an 11-year-old child with 
nephrocalcinosis and nephrolithiasis caused by a new mutation 
at CLCN5 gene.
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INTRODUCTION
Nephrocalcinosis is characterized by the 
deposition of calcium in the kidney parenchyma 
and tubules. It is associated with conditions that 
cause hypercalcemia, hyperphosphatemia, and 
the increased excretion of calcium, phosphate, 
and/or oxalate in the urine.1
Dent's disease is a rare cause of hypercalciuria 
without hypercalcemia. It is characterized by 
low molecular-weight (LMW) proteinuria, 
hypercalciuria, nephrocalcinosis, nephrolithiasis, 
proximal tubular dysfunction and renal failure in 
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adulthood.2,3 The physiopathology of tubulopathy 
is due to the inactivation of the CLCN-5 exchanger 
(chloride voltage-gated channel 5) at proximal 
tubules. Patients with a mutation at CLCN5 
gene encoding CLCN-5 channel are classified 
as having Dent's disease type 1, while patients 
with a mutation at OCRL gene encoding inositol 
polyphosphate-5-phosphatase are classified 
as Dent's disease type 2.4 Both forms of Dent’s 
disease are X-linked, and males, who are 
hemizygous, are affected more severely. Females, 
who are usually only mildly affected, are carriers.5
We present  an 11-year-old chi ld with 
nephrocalcinosis and nephrolithiasis who 
detected a new mutation in CLCN5 gene.
CASE REPORT
An 11-year  o ld  boy  was  re fer red  for 
nephrolithiasis and nephrocalcinosis detected 
at investigation of acute abdominal pain in 
emergency department. He denied any renal 
disease, trauma, diarrhea or constipation 
at past medical history. The parents is non-
consanguineous and grandmother had renal 
failure of unknown origine at medical family 
history. There was no pathological finding on 
the physical examination, including growth 
parameters and blood pressure according to 
age group. Laboratory findings were normal 
except hypercalciuria (9 mg/kg/d), 88% tubular 
phosphore reabsorbtion rate (TPR), low molecular 
weight proteinuria (Beta-2 microglobulin 
5080 mcg/L, n <250 mcg/L) in 24 hour urine, 
bilateral 4 mm non obstructive nephrolithiasis 
and nephrocalcinosis at ultrasonography. Urinary 
oxalate, citrate, uric acid, serum bicarbonate, 
phosphor, vitamin-D and parathormone values 
were also normal. Based on the clinical criteria of 
Dent's disease, genetic analysis was considered 
for Dent's disease in advance. The mutation in the 
CLCN-5 gene (c.2010_2010 del G or p.Asp671fs) 
was detected in frame shift and identified as a 
stop codon (Figure 1).
In the follow-up of the case, our patient has 
been treated with potassium citrate and thiazide 
for three years. There was no pathological finding 
to progression of end-stage renal failure in 
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laboratory tests. Genetic counseling was given to 
the patient's family for Dent’s disease.
DISCUSSION
According  to  the  labora tory  resu l t s , 
three groups can be formed in patients with 
nephrocalcinosis to make a differential diagnosis; 
hypercalciuria with hypercalcemia, hypercalciuria 
without hypercalcemia and hyperphosphaturia. 
Our patient fulfilled the criteria of the group 
of  hypercalc iuria  without  hypercalcemi 
rather than the groups of hypercalciuria with 
hypercalcemia and hyperphosphaturia among 
the three groups of nephrocalcinosis. Distal 
renal tubular acidosis, medullar sponge kidney, 
neonatal nephrocalcinosis, loop diuretics, 
inherited tubulopathies (Dent's disease etc.), 
chronic hypokalemia and beta thalassemia are 
the underlying diseases in association with the 
group of hypercalciuria without hypercalcemia at 
nephrocalcinosis.1 The clinical diagnosis of Dent’s 
disease is based on the presence of all of criteria: 
Low Molecular Weight (LMW) proteinuria 
(elevation of  urinary excretion of  beta2-
microglobulin, Clara cell protein and/or RBP by 
at least 5-fold above the upper limit of normal-
the pathognomonic finding of Dent’s disease), 
hypercalciuria (> 4 mg/kg in a 24 hour collection 
or > 0.25 mg Ca2+/ mg creatinine on a spot 
sample), and at least one of the following criteria: 
nephrocalcinosis, nephrolithiasis, hematuria, 
hypophosphatemia and chronic renal disease.6,7 
Nephrocalcinosis, nephrolithiasis, normal blood 
pH, LMW proteinuria, hypercalciuria and lower 
TPR without hypercalcemia pointed out Dent's 
disease in our patient. Genetical analysis also 
confirmed the diagnosis with the mutation in 
CLCN-5 gene.
Al though CLCN5  gene  mutat ions  are 
shown in about 60% of patients with X-linked 
nephrolithiasis, OCRL gene mutations are in 15%. 
The both of gene are normal at remaining 25% 
patients.2,3 The exact prevalence of Dent's disease 
is undefined; to date, >250 families have been 
described.5 Hypercalciuria and nephrocalcinosis 
are prevalent at a rate of 95% and 75% in affected 
males, respectively. Progression to end-stage 
renal failure are at the 3rd-5th decades of life in 
30-80% of affected males.8,9 Due to be the initial 
report and at early-stage, we could not define 
genotype-phenotype correlations for novel 
mutation. Comparatively silent presentation 
of our patient may be specific aspect for this 
mutation at early stage. The other potential 
(including end-stage renal failure) or unreported 
aspects of disease may be met later in our patient 
with this novel mutation. But it is definite that 
Dent's disease may be seen in patients with this 
mutation at CLCN5 gene.
In the absence of therapy targeting for the 
molecular defect, the current care of patients 
with Dent’s disease is supportive, focusing 
Figure 1. Themutation (c.2010_2010 del G or p.Asp671fs) in the CLCN-5 gene 
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on the prevention of nephrolithiasis and 
nephrocalcinosis. Thiazide diuretics can be used 
to treat hypercalciuria.10,11 
Up to rarely seen, we think the new mutation 
in the CLCN-5 gene will enlight and contribute the 
potential findings and studies relevant to Dent's 
disease in future. Dent's disease should be kept 
in mind in nephrocalcinosis with hypercalciuria, 
LMW proteinuria and normal blood pH at male 
patients. n
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